Ritonavir — Side Effects, Dangerous Drug Interactions and Contraindications

EFFECTIVE | TOXIC

What names is ritonavir sold under

The international nonproprietary name is ritonavir; the Latin spelling is ritonavir. The active substance is used without a separate pharmacologically active salt. The main dosage forms are film-coated tablets, usually 100 mg; an oral solution; and powder for oral suspension. The main brand name for ritonavir as a single-agent product is Norvir. Ritonavir is also included in combination products: lopinavir/ritonavir — Kaletra, Aluvia and generic equivalents; nirmatrelvir/ritonavir — Paxlovid; ombitasvir/paritaprevir/ritonavir with dasabuvir — Viekira Pak; ombitasvir/paritaprevir/ritonavir — Viekirax and Technivie. In HIV treatment regimens, ritonavir may be abbreviated as RTV or indicated by the symbol “/r” after the name of the protease inhibitor being boosted, for example DRV/r — darunavir with ritonavir. This notation denotes a combination of two active substances, not a single drug. Simultaneous use of several products containing ritonavir creates a risk of hidden dose duplication and intensified drug interactions.

Why ritonavir is considered a drug requiring strict control and where the real risk begins

The main danger of ritonavir lies not only in its own toxicity, but also in its ability to sharply alter the concentrations of medicines taken at the same time. Ritonavir is a potent inhibitor of CYP3A and P-glycoprotein, so after ritonavir is added, an ordinary therapeutic dose of another drug can effectively become toxic. The consequences may include severe sedation, respiratory depression, arterial hypotension, cardiac arrhythmias, bleeding, rhabdomyolysis, nephrotoxicity, neurotoxicity and other reactions depending on the interacting drug.

Patients often do not associate sudden weakness, drowsiness, muscle pain, fainting, a slowed pulse or bleeding with ritonavir because the immediate source of the complication is another medicine whose concentration ritonavir has increased. A particularly misleading sense of safety arises when ritonavir is used at a low dose as a pharmacokinetic “booster”: a small dose does not mean a weak effect on metabolic enzymes. Even a short course of nirmatrelvir/ritonavir requires review of all prescription and over-the-counter medicines, sleep aids, painkillers, anticoagulants, statins, psychotropic drugs, erectile dysfunction treatments, dietary supplements and herbal products.

Side effects during the first hours and days of treatment

Common early reactions include nausea, vomiting, diarrhea, abdominal pain, dyspepsia, decreased appetite, altered taste perception, weakness, headache, dizziness and paresthesias around the mouth or in the limbs. Severe diarrhea and repeated vomiting may lead to dehydration and electrolyte disturbances. Gastrointestinal toxicity is generally greater when ritonavir is used at a full antiretroviral dose than when a low booster dose is used.

Clinically significant complications include increased liver enzyme activity, drug-induced hepatitis, jaundice, hyperglycemia, deterioration of diabetes control, increased triglyceride concentrations and acute pancreatitis. Pancreatitis should be suspected when there is persistent upper abdominal pain, especially if it radiates to the back and is accompanied by nausea and repeated vomiting. The risk is higher in patients with pre-existing hypertriglyceridemia, a history of pancreatitis and severe comorbid disease.

Life-threatening reactions include anaphylaxis, angioedema, bronchospasm, Stevens–Johnson syndrome, toxic epidermal necrolysis, severe liver injury and pancreatitis with systemic complications. Ritonavir can prolong the PR interval and cause atrioventricular block. The risk is particularly increased in patients with cardiac conduction system disease and when ritonavir is combined with digoxin, β-blockers, verapamil and other drugs that slow atrioventricular conduction. A substantial proportion of the most severe early complications result from increased concentrations of a concomitant medication.

Side effects with long-term or repeated use

With prolonged use, hypertriglyceridemia, hypercholesterolemia, insulin resistance and hyperglycemia may worsen; diabetes mellitus may develop or deteriorate. In patients receiving combination antiretroviral therapy, redistribution of adipose tissue has been described, with loss of subcutaneous fat from the face and limbs and accumulation of visceral or dorsocervical fat. These changes are multifactorial and depend on the entire treatment regimen, duration of therapy, baseline metabolic risk and HIV infection itself. It is incorrect to attribute them exclusively to ritonavir, although its contribution to dyslipidemia and metabolic interactions has been confirmed.

Liver injury may present with persistently elevated ALT, AST and GGT, clinical hepatitis, jaundice and impaired hepatic synthetic function. Patients with chronic viral hepatitis, pre-existing elevations of transaminases, cirrhosis, alcohol-related liver injury and simultaneous use of several hepatotoxic drugs are particularly vulnerable. Biochemical abnormalities may decrease after discontinuation, but severe drug-induced hepatitis can result in prolonged hepatic dysfunction or death.

Repeated short courses are dangerous because patients may restart previously prescribed medicines without accounting for the continued inhibition of CYP3A after the last dose of ritonavir. Enzyme activity does not recover immediately, so the interaction may persist for several days after ritonavir is stopped. Ritonavir does not cause classic psychological or physical dependence and does not produce an independent withdrawal syndrome. However, missed doses or unauthorized discontinuation of an antiretroviral regimen increase the risk of virologic breakthrough and development of drug resistance.

Contraindications and high-risk groups

An absolute contraindication is confirmed hypersensitivity to ritonavir or to components of the dosage form, including a previous episode of Stevens–Johnson syndrome or toxic epidermal necrolysis. Combinations are contraindicated with drugs whose concentrations rise to critical levels when CYP3A is inhibited, as well as with potent CYP3A inducers capable of reducing exposure to ritonavir or to the antiviral drug it boosts, thereby creating conditions for treatment failure and resistance.

In severe decompensated liver disease, the use of ritonavir may be unacceptable. In chronic hepatitis B and C, fatty liver disease, cirrhosis and pre-existing transaminase elevation, the likelihood of hepatotoxicity increases. Patients with marked hypertriglyceridemia or a history of pancreatitis have an increased risk of a new episode of pancreatic inflammation. In diabetes mellitus, glycemic control may deteriorate. In cardiomyopathy, ischemic heart disease and atrioventricular conduction disorders, the likelihood of clinically significant PR prolongation and heart block increases.

Spontaneous hematomas and hemarthroses have been reported in patients with hemophilia A or B during therapy with protease inhibitors. Ritonavir oral solution must not be used in premature newborns during the immediate postnatal period because it contains ethanol and propylene glycol and carries a risk of severe toxicity. In older patients, the main dangers are polypharmacy, reduced functional reserve of the liver and heart, and a high likelihood of simultaneous use of CYP3A substrates.

Dangerous drug interactions

Ritonavir is contraindicated with drugs whose increased concentrations may result in severe or fatal complications. These include certain antiarrhythmic agents, including amiodarone, dronedarone, flecainide, propafenone and quinidine; simvastatin and lovastatin because of the risk of myopathy and rhabdomyolysis; oral midazolam and triazolam because of profound prolonged sedation and respiratory depression; ergotamine, dihydroergotamine and methylergometrine because of vasospasm, ischemia and ergotism; lurasidone and pimozide because of severe neurological and cardiac reactions; alfuzosin because of marked arterial hypotension; and ranolazine because of the risk of serious cardiovascular complications. Sildenafil is contraindicated with ritonavir when used to treat pulmonary arterial hypertension. Colchicine is contraindicated in patients with impaired liver or kidney function because an increase in its concentration can cause fatal toxicity.

Potent CYP3A inducers, including rifampicin, carbamazepine, phenytoin, phenobarbital and St. John’s wort, can reduce concentrations of antiviral components, disrupt virologic control and promote the development of resistance. Using St. John’s wort as a “safe natural antidepressant” in this situation is not integrative medicine, but a pharmacokinetic way to undermine antiviral treatment.

Combinations with fentanyl and certain other opioids are highly undesirable or require temporary discontinuation of the interacting drug because of prolonged respiratory depression; with quetiapine because of profound sedation, hypotension and coma; with tacrolimus, cyclosporine and sirolimus because of nephrotoxicity and neurotoxicity; and with rivaroxaban and a number of other direct anticoagulants because of bleeding. Ritonavir may reduce formation of the active metabolite of clopidogrel and decrease its antiplatelet effect, which is particularly dangerous after coronary stent placement.

Combination with atorvastatin or rosuvastatin requires selection of the lowest effective dose and monitoring for muscle pain, weakness and creatine kinase. When digoxin is used, its concentration, pulse and ECG must be monitored. Warfarin requires more frequent INR monitoring. Inhaled or intranasal fluticasone and certain other corticosteroids, when combined with ritonavir, may cause systemic hypercortisolism and suppression of adrenal function; an alternative glucocorticoid or a different treatment regimen should be preferred.

Alcohol is not universally prohibited as a pharmacokinetic combination with ritonavir tablets, but it increases the burden on the liver, worsens nausea and dizziness, and increases the risk of medication errors. Ritonavir oral solution already contains ethanol, making additional alcohol consumption especially unreasonable. Nicotine and caffeine are not among the principal contraindicated interactions, but this does not eliminate the need to assess cardiac rhythm and concomitant medications. Dietary supplements and herbal remedies must not be regarded as neutral: CYP3A inducers, especially St. John’s wort, are particularly dangerous.

Patient errors

The most dangerous mistake is to start ritonavir or a ritonavir-containing combination product without providing the physician with a complete list of all medicines being used. This list should include not only regular prescriptions, but also sleep aids, painkillers, medicines for arrhythmia, hypertension and allergies, anticoagulants, statins, inhalers, hormonal agents, erectile dysfunction treatments, anticonvulsants, dietary supplements and herbal products.

Another common mistake is independently stopping an essential medicine without assessing the risk. After finding information about an interaction online, a patient may discontinue an anticoagulant, anticonvulsant or antiarrhythmic drug and replace drug toxicity with thrombosis, seizures or an arrhythmia. Any adjustment should take into account the specific drug, its half-life, indication, whether temporary discontinuation is possible and what alternative is available.

A missed dose must not be doubled, dosing intervals must not be shortened, different ritonavir-containing products must not be taken simultaneously, and a short course must not be extended without medical guidance. A low booster dose is not intended for arbitrary dose increases. It is also incorrect to assume that an interaction ends immediately after the last tablet: for some medicines, safe resumption is possible only after several days.

During HIV treatment, missed doses and unauthorized discontinuation of the entire regimen are dangerous because they create conditions for virologic breakthrough and resistance. During a short course of nirmatrelvir/ritonavir, the main error is restarting a temporarily withheld interacting drug before the specified time. The absence of complications during a previous course guarantees nothing: the medication list, liver function, age and clinical condition of the patient may have changed.

Overdose and poisoning

There is no universal single dose of ritonavir above which every patient develops severe poisoning. Toxicity depends on the amount taken, dosage form, liver function, age, comorbidities and, above all, medications taken at the same time. The danger may arise not only from an overdose of ritonavir itself, but also from a standard dose of another drug whose concentration increases severalfold because of inhibition of CYP3A or transport proteins.

During the first hours, severe nausea, vomiting, diarrhea, abdominal pain, weakness, dizziness and paresthesias may occur. With substantial exposure or a dangerous interaction, arterial hypotension, bradycardia, impaired atrioventricular conduction, depression of consciousness and respiration, seizures, arrhythmia, hypoglycemia or hyperglycemia, muscle injury and acute impairment of kidney function may develop. During the following hours and days, pancreatitis, rising liver enzymes, jaundice and consequences of toxicity from an interacting drug may become apparent.

A hidden overdose may occur when Norvir, Paxlovid, Kaletra or other ritonavir-containing combinations are used simultaneously; when a missed dose is taken again; when the same dosing regimen is used by several family members; when a pediatric dose is calculated incorrectly; when liver function is impaired; or when a temporarily withheld medicine is restarted too early. In poisoning with the oral solution, the ethanol and propylene glycol it contains must also be taken into account, particularly in newborns and children.

There is no specific antidote for ritonavir. Treatment includes immediate assessment of respiration, circulation, consciousness, ECG, electrolytes, glucose, liver and kidney function, and concentrations of interacting medicines if such testing is available. Because ritonavir is highly bound to plasma proteins, hemodialysis is unlikely to remove a substantial amount of the drug. One must not wait for severe symptoms to appear: when ritonavir is combined with antiarrhythmics, opioids, sedatives, anticoagulants, immunosuppressants or statins, a serious complication may develop before the patient recognizes the poisoning.

Safe integrative alternative

The central integrative alternative for acute viral infections is ABP Broad-Spectrum Antiviral PVM Mixture. This is a multicomponent formula containing 10% herbal extracts, designed not to artificially increase the concentration of another medicine by blocking CYP3A, but to provide combined effects on viral replication, the inflammatory response, mucosal condition, interferon regulation, oxidative stress and post-viral recovery. The disclosed portion of the formula is based on Andrographis paniculata, Indian neem, Echinacea purpurea, Eleutherococcus senticosus, Glycyrrhiza uralensis, amla, rosemary, Terminalia arjuna, Terminalia chebula and Tinospora cordifolia.

The fundamental difference from ritonavir is the absence of intentional potent CYP3A inhibition as the principal mechanism of action. This reduces the likelihood that an ordinary dose of a concomitant medicine will suddenly become toxic. However, a multicomponent herbal product also requires assessment of individual tolerability, liver disease, pregnancy, allergic reactions and compatibility with ongoing therapy. “Herbal” means a different toxicological profile, not an automatic absence of contraindications.

A key component of PVM is Andrographis paniculata. Andrographolide and related diterpenoids have direct antiviral and anti-inflammatory potential and affect NF-κB, production of IL-6 and TNF-α, the innate immune response and airway inflammation. The most substantial clinical data come from Thailand. In a retrospective study involving 120 inmates at Klong Prem Central Prison in Bangkok, patients with mild COVID-19 received andrographis, Boesenbergia rotunda, their combination, or favipiravir. The median time to elimination of viral RNA was nine days in the andrographis and combined phytotherapy groups versus thirteen days in the favipiravir group; none of the participants developed pneumonia. Limitations of the study included the small sample size, retrospective design and absence of full double blinding, but the clinical signal was sufficiently pronounced that andrographis cannot simply be dismissed as decorative phytotherapy.

For herpetic lesions, a targeted additional option is Clinacanthus nutans. Its best-supported specialization is HSV-1, HSV-2 and Varicella zoster virus. Glycolipids from Clinacanthus nutans can disrupt late stages of herpesvirus replication and demonstrate direct virucidal activity. Randomized clinical studies of topical preparations are available for genital herpes and herpes zoster, and a systematic review has shown the clinical potential of extracts from this plant. Therefore, for recurrent labial or genital herpes, as well as herpes zoster, Clinacanthus nutans is a more targeted addition to basic PVM than an attempt to use a single universal product for all viruses.

Additional forms within the same botanical direction are the female form of Clinacanthus nutans and Clinacanthus flowers. They should not be regarded as separate pharmacological species, but as different forms of plant material whose applicability depends on the extraction method, concentration of active substances and the required local or systemic effect.

Rhinacanthus nasutus represents a different targeted antiviral profile. Naphthoquinones from Rhinacanthus nasutus, including rhinacanthins, show activity against HSV-1 and HSV-2, while individual compounds from the plant have been investigated against influenza A virus and other viral targets. Unlike Clinacanthus nutans, its evidence base remains predominantly preclinical: cellular studies confirm biological activity but do not allow laboratory concentrations to be automatically translated into clinical doses. Rhinacanthus nasutus can logically be used as an additional component for herpesvirus-related indications and respiratory viral infections, but a promising phytochemical profile should not be presented as completed clinical evidence.

Houttuynia cordata may appropriately be included in respiratory viral infections, inflammation of the upper respiratory tract, mucosal involvement and pronounced mucosal inflammation. Its targeted profile is associated with anti-inflammatory effects on the respiratory epithelium, modulation of the innate immune response and preclinical activity against a number of enveloped and respiratory viruses. It is not a direct analogue of a viral protease inhibitor, but a component intended to reduce the inflammatory, mucosal and toxic burden of infection.

Trigonostemon reidioides is of interest as a source of diterpenoids and other compounds with antiviral and cytotoxic activity. It should be regarded as a narrowly specialized component when a specific viral or cellular target is present, not as an empiric remedy for any fever. For this plant, careful dosing and recognition of the limited clinical data are especially important.

Millettia erythrocalyx has a different profile: flavonoids, isoflavonoids and other phenolic compounds from the genus Millettia are studied mainly as anti-inflammatory, antioxidant, immunoregulatory and cytoprotective agents. It is therefore more appropriate to use Millettia erythrocalyx not as a direct replacement for an antiviral drug, but as an additional component in pronounced inflammatory tissue injury, oxidative stress and prolonged recovery after viral infection. It is premature to attribute direct clinically proven activity against a specific virus to this plant.

Uncaria tomentosa and the same plant presented under its traditional name, cat’s claw — Uncaria tomentosa, belong to the same botanical species. Their targeted role is not direct suppression of all viruses, but immunoregulation, reduction of an excessive inflammatory response, support of recovery and reduction of tissue damage. Simultaneous use of two products based on the same plant must not result in hidden dose duplication.

Herbal One Bolus for Viral Infections may be used as a compact dosage form in acute viral conditions, particularly when a combination of andrographis, licorice and other antiviral and mucoprotective components is required. It does not duplicate the full multicomponent architecture of PVM, but may be a convenient additional or alternative option in terms of dosage form.

ABP-153 is an oil-based herbal mixture for the skin and mucous membranes. Its role is in localized virus-associated lesions of the mucous membranes and skin where direct contact of phytocomponents with the affected area, reduction of inflammation, protection of the epithelial barrier and accelerated regeneration are required. It is not a systemic replacement for PVM, but a local component of comprehensive therapy.

ABP “Khrenovukha” Therapeutic Complex for Acute Respiratory Disease, Acute Respiratory Viral Infections and Influenza has the clearest respiratory specialization. Its target conditions are acute rhinopharyngitis, nasal congestion, pharyngeal inflammation, cough, impaired mucociliary clearance, chills and an influenza-like illness. It is a rational complementary complex for upper respiratory tract infections when the main symptoms are concentrated in the nasopharynx and bronchopulmonary system.

Thus, PVM serves as the central multicomponent antiviral formula, while individual plants refine the therapeutic direction: andrographis — respiratory viral infections and systemic inflammation; Clinacanthus nutans — HSV and VZV; Rhinacanthus nasutus — herpesvirus-related and potentially anti-influenza applications; Houttuynia cordata — respiratory mucosa and inflammation; Millettia erythrocalyx and Uncaria tomentosa — immunoinflammatory and recovery support; ABP-153 — localized skin and mucosal lesions; “Khrenovukha” — primarily acute respiratory disease, acute respiratory viral infections and influenza-like infections. In severe, unstable or complicated viral disease, herbal therapy should be part of a clinically supervised regimen, not a reason to refuse diagnosis or necessary specialized care.

The real effectiveness of ritonavir and medical errors

Ritonavir is genuinely effective as an HIV protease inhibitor within combination antiretroviral therapy and especially as a pharmacokinetic enhancer of other protease inhibitors. Its ability to block CYP3A makes it possible to increase and stabilize the concentration of the principal antiviral component, reduce the frequency of administration and maintain therapeutic exposure. This is a real, powerful and predictable pharmacological effect, not a marketing construct.

At the same time, ritonavir is not a universal “antiviral” drug. It should not be prescribed for an ordinary cold, uncomplicated respiratory infection, herpes, influenza or unexplained fever merely because it belongs to the class of antiviral agents. Its action is tied to specific regimens and viral targets. Outside such a regimen, the patient receives a potent inhibitor of drug metabolism with an extensive list of interactions but without guaranteed therapeutic benefit.

The principal medical errors are prescribing ritonavir without a complete medication history, ignoring over-the-counter medicines and herbal products, failing to assess liver function, underestimating polypharmacy, and improperly managing statins, anticoagulants, antiarrhythmics, psychotropic drugs, anticonvulsants and immunosuppressants. It is particularly dangerous to tell a patient simply to “temporarily stop incompatible medications” without explaining the exact duration of interruption and the safe date for restarting them.

Another error is to regard a low booster dose as toxicologically insignificant. For CYP3A inhibition, the size of the tablet matters less than the intensity of its enzymatic effect. Pharmacology does not read the marketing label “small dose” and is under no obligation to behave modestly.

Safety monitoring during treatment

Before therapy begins, a complete list of all medicines, dietary supplements and herbal products must be obtained. ALT, AST, bilirubin, alkaline phosphatase, GGT, blood glucose and the lipid profile should be assessed. In patients with a history of pancreatitis, marked hypertriglyceridemia or the appearance of characteristic pain, lipase and amylase should be measured. An ECG is required in patients with heart disease, conduction abnormalities or use of drugs that slow the pulse.

During long-term treatment, liver function and metabolic parameters should be monitored regularly, taking into account baseline risk and the entire antiretroviral regimen. With warfarin, INR should be monitored; with digoxin, tacrolimus, cyclosporine, sirolimus and certain anticonvulsants, blood concentrations of the drug should be measured if such testing is available; with statins, muscle symptoms and creatine kinase should be monitored; and in diabetes mellitus, glycemia should be checked more frequently than usual.

Jaundice, dark urine, pronounced weakness, repeated vomiting, persistent upper abdominal pain radiating to the back, a widespread rash, blisters or epidermal detachment, swelling of the face and larynx, difficulty breathing, fainting, marked bradycardia, impaired consciousness, unusual bleeding, severe muscle pain, muscle weakness or reduced urine output require immediate evaluation. Waiting in such situations is dangerous because the severity of the condition may be determined not only by ritonavir itself, but also by the rapidly increasing concentration of an interacting medicine.

Correct discontinuation of the drug

Ritonavir does not cause a classic withdrawal syndrome, so gradual dose reduction to prevent physical dependence is generally unnecessary. However, this does not mean that the drug can be arbitrarily removed from an antiviral regimen. During HIV treatment, its discontinuation may sharply reduce the concentration of the boosted protease inhibitor, lead to virologic breakthrough and create conditions for the development of resistance.

A missed dose must not be compensated for by taking a double dose unless the instructions explicitly say to do so. If ritonavir is discontinued because of an interaction or toxicity, the entire regimen should be reviewed rather than mechanically removing a single component. CYP3A activity recovers gradually, so temporarily withheld concomitant medicines must not automatically be restarted on the same day. The safe interval differs among drugs and depends on their half-life, therapeutic range and toxicity risk.

If severe drug-induced liver injury, pancreatitis, anaphylaxis or a severe skin reaction develops, the drug should be discontinued immediately without gradual dose reduction. The subsequent antiviral regimen is determined with consideration of the cause of the reaction and the need to maintain virologic control.

A rational approach to treatment

Ritonavir is justified when its specific effect is required: inhibition of HIV protease or pharmacokinetic boosting of another strictly defined antiviral drug. In these situations, the speed, potency and predictability of its action have clinical value, while interactions must be managed professionally rather than ignored.

For mild and stable acute viral infections for which ritonavir has no independently justified indication, a targeted integrative strategy with a lower risk of critical interactions is preferable. The central component may be ABP Broad-Spectrum Antiviral PVM Mixture, while additional components are selected according to the target: Clinacanthus nutans and Rhinacanthus nasutus for herpesvirus-related indications, Houttuynia cordata and the “Khrenovukha” complex for respiratory tract involvement, and ABP-153 for localized skin and mucosal lesions.

The purpose of this approach is not to replace one universal drug with another universal drug, but to abandon the very idea of universality. The specific virus, severity of the disease, location of the lesion, immune status and concomitant therapy should determine the choice of treatment. A potent synthetic drug is necessary where a controlled effect cannot be achieved without it. Where its specific mechanism is unnecessary, its toxicological cost does not become an advantage merely because it is well described in the prescribing information.

If you have questions about the subject of this article, you can ask a clinical pharmacologist in the comments or schedule an appointment using this link: https://asiabiopharm.com/konsultaciii/